Key facts
- Buzzreach’s last known valuation is $15.6M (Nov 2025).
- It has raised $11.8M; the latest was Later Stage VC ($1.8M) in Nov 2025.
- Notable investors include ANOBAKA, Japan Finance Corporation, Globis Capital Partners, Aozora Corporate Investment, Aozora Bank — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Buzzreach
- ·The full record, as it builds
Funding rounds
No funding rounds for Buzzreach are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Buzzreach
Developer of a healthcare technology platform designed to connect clinical trial patients with pharmaceutical companies. The company's platform offers a bridge for patients to connect with the clinical trials that they are eligible to participate in and carefully cultivate patient communities to ensure that their health information reaches the right eyes and ears, enabling medical professionals to understand the value of trials and contribute towards patients' understanding of health and wellness.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2017
- Employees
- 11
- Website
- buzzreach.co.jp/
- Ownership
- Privately Held (backing)
Buzzreach doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Buzzreach shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Buzzreach in its N-PORT filings yet. We sweep new filings monthly.